UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations Clinical and genomic characterization of metastatic small cell/ neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AARCWest Coast Prostate Cancer Dream Team (WCDT). Authors*: Eric Jay Small, Rahul Raj Aggarwal, Jiaoti Huang, Artem Sokolov, Li Zhang, Joshi J. Alumkal, Jack Youngren, Charles J. Ryan, Adam Foye, Robert Evan Reiter, Christopher P. Evans, Martin Gleave, Owen Witte, Josh Stuart, Theodore C. Goldstein, George V. Thomas, Lawrence D. True, Himisha Beltran, Mark A. Rubin, Tomasz M. Beer Abstract #: 5019 Presentation Date/Time: Saturday, June 4: 4:45 - 6:00 PM Location: Hall D1 Poster Discussion Session: Genitourinary (Prostate) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr 5019) Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the idea that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common cellular responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate cancer therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to overcome treatment resistance and profoundly improve the care of men affected by this fatal disease. This team is a six institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of British Columbia, Oregon Health and Sciences University, with UCSF as the lead administrative site. http://cancer.ucsf.edu/people/profiles/small_eric.3671 *UCSF authors in bold 40
Presentations Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C ) and vemurafenib (V) in BRAF-mutant melanoma. Authors*: Adil Daud, Anna C. Pavlick, Antoni Ribas, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas Gajewski, Igor Puzanov, Jessie J. Hsu, Daniel O. Koralek, Nicholas W. Choong, Grant A. McArthur Abstract #: 9510 Presentation Date/Time: Saturday, June 4: 4:45 - 6:00 PM Location: E354b Poster Discussion Session: Melanoma/Skin Cancers Citation: J Clin Oncol 34, 2016 (suppl; abstr 9510) Daud Research Interests: Our group at UCSF is focused on developing new immunotherapy agents and specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL- 12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets of melanoma (and potentially other cancers). http://cancer.ucsf.edu/people/profiles/daud_adil.3622 *UCSF authors in bold 41
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Phase II trials of ce
Page 11 and 12: Presentations CRS-207 immunotherapy
Page 13 and 14: Presentations Long-term OS for pati
Page 15 and 16: Presentations Randomized phase 2 st
Page 17 and 18: Presentations Genomic Profiling to
Page 19 and 20: Presentations Validating RNAseq-sig
Page 21 and 22: Presentations Phase I/II study of V
Page 23 and 24: Presentations Clinical and genomic
Page 25 and 26: Presentations IMAAGEN trial safety
Page 27 and 28: Presentations Immunogenicity of sip
Page 29 and 30: Presentations Pembrolizumab for adv
Page 31 and 32: Presentations Novel T cell exhausti
Page 33 and 34: Presentations Correlation between m
Page 35 and 36: Presentations ATLAS: A randomized,
Page 37 and 38: Presentations A prospective analysi
Page 39: Presentations Circulating Biomarker
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54: Presentations Randomized phase II t
Page 55 and 56: Presentations Phase II trial with t
Page 57 and 58: Presentations Academic and Communit
Page 59 and 60: Presentations Prevention of everoli
Page 61 and 62: Presentations A phase 2 randomized,
Page 63 and 64: Presentations PD-L1 expression, Can
Page 65 and 66: Presentations The Heart of the Matt
Page 67 and 68: Presentations 4-year results of the
Page 69 and 70: Presentations Impact of landmark re
Page 71 and 72: Presentations Phase II study of ali
Page 73 and 74: Presentations Can lay health worker
Page 75 and 76: Presentations Medical Management of
Page 77 and 78: Presentations Prospective evaluatio
Page 79 and 80: Presentations A phase II randomized
Page 81 and 82: Presentations Early, molecular dete
Page 83 and 84: Presentations Metastatic melanoma,
Page 85 and 86: Presentations Three-year overall su
Page 87 and 88: Presentations Heritage: A phase III
Page 89 and 90: Presentations Determining barriers
Page 91 and 92:
Presentations Controversies in Loca
Page 93 and 94:
Presentations A pharmacodynamic stu
Page 95 and 96:
Presentations Final results of a ph
Page 97 and 98:
Presentations Comparative performan
Page 99 and 100:
Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?